v3.22.2.2
Consolidated Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]            
Revenues, net $ 2,400,311 $ 2,550,046 $ 8,919,312 $ 7,501,535 $ 9,889,433 $ 17,122,520
Cost of Sales 998,320 1,269,005 5,010,704 3,995,792 5,143,468 11,415,198
Gross Profit 1,401,991 1,281,041 3,908,608 3,505,743 4,745,965 5,707,322
Operating Expenses            
Loss on Inventory Investment 1,285 1,226,426 1,226,426
Wage and salary expense 937,062 1,015,816 3,185,144 2,878,237    
Professional fees 95,275 205,457 307,341 757,263    
Accounting and legal expense 191,611 98,867 567,690 462,626    
Technology expense 298,586 338,637 842,433 678,110    
Loss on Impairment of Goodwill         (0) 725,973
General and Administrative 286,488 917,105 1,484,709 2,013,050 8,811,832 7,488,011
Total Operating Expenses 1,809,022 2,577,167 6,387,317 8,015,712 10,038,258 8,213,984
Operating Loss (407,031) (1,296,126) (2,478,709) (4,509,969) (5,292,293) (2,506,662)
Nonoperating income (expense)            
Interest income 8,396 8,396    
Gain on disposal of asset 4,100    
Interest Expense (130,107) (5,622) (140,626) (21,574) (23,590) (29,389)
Total nonoperating expense (121,711) (5,622) (128,130) (21,574)    
Net Loss (528,742) (1,301,748) (2,606,839) (4,531,543) (5,315,883) (2,536,051)
Net loss attributable to TRxADE Health, Inc. (503,003) (1,301,748) (2,546,913) (4,531,543) $ (5,315,883) $ (2,536,051)
Net loss attributable to non-controlling interests $ (25,739) $ (59,926)    
Net Loss per Common Share – Basic and Diluted $ (0.06) $ (0.16) $ (0.31) $ (0.56) $ (0.65) $ (0.33)
Weighted average Common Shares Outstanding – Basic and Diluted 8,249,653 8,163,522 8,203,202 8,126,689 8,136,740 7,705,620